U.S. markets close in 3 hours 54 minutes
  • S&P 500

    4,285.15
    +11.11 (+0.26%)
     
  • Dow 30

    33,967.38
    -12.94 (-0.04%)
     
  • Nasdaq

    12,989.88
    +51.76 (+0.40%)
     
  • Russell 2000

    1,995.52
    +8.21 (+0.41%)
     
  • Crude Oil

    90.07
    +1.96 (+2.22%)
     
  • Gold

    1,773.40
    -3.30 (-0.19%)
     
  • Silver

    19.57
    -0.16 (-0.82%)
     
  • EUR/USD

    1.0115
    -0.0065 (-0.64%)
     
  • 10-Yr Bond

    2.8590
    -0.0340 (-1.18%)
     
  • GBP/USD

    1.1974
    -0.0078 (-0.64%)
     
  • USD/JPY

    135.3420
    +0.2520 (+0.19%)
     
  • BTC-USD

    23,462.74
    +75.88 (+0.32%)
     
  • CMC Crypto 200

    559.93
    +2.20 (+0.39%)
     
  • FTSE 100

    7,541.85
    +26.10 (+0.35%)
     
  • Nikkei 225

    28,942.14
    -280.63 (-0.96%)
     

Heartflow Charts NYSE Debut IPO Via $2.4B SPAC Deal

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Heartflow Holding Inc (NYSE: HFLO) aims to bring its noninvasive, artificial intelligence (AI)-based test for coronary heart disease to more doctors and patients via a SPAC merger with Longview Acquisition Corp II (NYSE: LGV).

  • Once the deal, valued at an enterprise value of about $2.4 billion, is complete, the resulting public company will operate under HeartFlow's banner with the NYSE ticker HFLO.

  • The company offers a test that uses artificial intelligence to build an individualized map of each patient's cardiovascular anatomy and function to diagnose coronary artery disease.

  • The merger is expected to close in the fourth quarter of this year, pending customary conditions and SEC approval.

  • Longview II is backed by Glenview Capital Management, which previously merged its elder Longview Acquisition Corp with the portable ultrasound maker Butterfly Network Inc (NYSE: BFLY) in a $1.5 billion SPAC deal completed earlier this year.

  • The solution allows cardiologists to determine the severity of a coronary blockage without requiring an invasive cardiac catheterization.

  • Price Action: LGV shares are trading higher by 0.41% $9.90 in the market session on the last check Friday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.